Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proposed Legislation Would Help FDA Stop Illicit Opioids At Border -- And More

Executive Summary

US FDA would gain more of the ability it seeks to interdict illicit opioids at the border under legislation proposed by House Energy & Commerce Committee's top Democrat. But would there be collateral damage to the legitimate pharmaceutical industry?

You may also be interested in...



Opioids: US Senate Committee Chairman's Discussion Drafts Broadly Reflect FDA Priorities

Agency would be allowed to require blister packaging for approved opioids, and would have to do more to coordinate with US Customs and Border Protection to detect illicit drugs at the border, under legislative proposals unveiled by Senate HELP Committee Chairman Lamar Alexander.

Bipartisan Consensus Emerges To Let FDA Destroy Unlabeled Illicit Opioids

Congress is intent on passing legislation addressing the opioid crisis and one measure that is picking up steam would give FDA the authority to destroy illegal opioids at international mail facilities instead of sending them back.  

Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities

US FDA commissioner says primary use of proposed budget boost would be border security; budget documents state that special opioid epidemic funding also would support regulatory science and diagnostic development.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel